Antiviral Drug Market to Reach $90.6 Billion by 2035

The global antiviral drug market, valued at $61.2 billion in 2025, is projected to grow steadily at a CAGR of 4.0%, reaching approximately $90.6 billion by 2035. The market expansion is driven by rising viral disease burden, advancements in drug development, and increasing global healthcare expenditure. A key macro driver fueling this growth is the escalating prevalence of viral infections worldwide. According to the World Health Organisation (WHO), an estimated 296 million people are living with chronic Hepatitis B, while around 58 million people are infected with Hepatitis C globally. Additionally, approximately 39 million people are living with HIV, necessitating long-term antiviral therapies. These statistics highlight a sustained and growing demand for antiviral treatments across therapeutic areas, directly supporting market expansion.

Browse the full report description of “Antiviral Drug Market Size, Share & Trends Analysis Report by Drug Class (Protease Inhibitors, Integrease Strand Transfer Inhibitors (INSTIs), Entry & Fusion Inhibitors, Neuraminidase Inhibitors, RNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Combination Antiviral Therapies), by Indication (HIV/AIDS, Hepatitis, Influenza, Herpes Simplex Virus, Human Papillomavirus), by Drug Type (Small Molecules Antivirals, Biologics, RNA Based Therapies ), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/antiviral-drug-market

Government and public health initiatives are further strengthening the demand. The WHO Global Health Sector Strategy on Viral Hepatitis aims to eliminate viral hepatitis as a public health threat by 2030, driving large-scale screening and treatment programs. Similarly, national healthcare systems across the U.S., Europe, and Asia are increasing investments in access to antiviral drugs and pandemic preparedness, as seen during and after COVID-19.

Among product types—Small Molecule Antivirals, Biologics Antivirals, and RNA-based Therapies—the RNA-based Therapies segment is growing the fastest. This is due to their high specificity, rapid development cycles, and effectiveness against emerging viral strains. RNA-based antivirals, including mRNA and siRNA-based therapeutics, are increasingly being adopted for their ability to target viral replication at the genetic level. Their relevance has grown significantly following global vaccine and therapeutic innovations during the COVID-19 pandemic.

Key Industry Developments Include:

• In March 2026, Shionogi announced that Japan approved a supplemental indication for its oral antiviral XOCOVA (ensitrelvir) for post-exposure prophylaxis of COVID-19. This makes it the first and only oral antiviral approved in Japan for this use, expanding the commercial and clinical role of COVID antivirals in the market.

• In September 2025, Gilead announced a partnership with PEPFAR to provide its twice-yearly injectable lenacapavir, a multi-stage HIV antiviral, at no profit in many low- and lower-middle-income countries. This initiative supports large-scale adoption of next-generation long-acting antivirals and strengthens demand momentum in the global antiviral drugs market.

The combination of technological advancements, regulatory support, and rising viral disease prevalence continues to drive robust growth in the antiviral drug market globally.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Drug Class
  • By Indication
  • By Drug Type
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
  • Competitive Landscape -Gilead Sciences lnc, Pfizer lnc, Merck & Co. Inc., Johnson and Johnson, and Glaxosmithkline plc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antiviral Drug Market Report Segment

By Drug Class

• Protease Inhibitors
• Integrase Strand Transfer Inhibitors (INSTIs)
• Entry & Fusion Inhibitors
• Neuraminidase Inhibitors (Influenza)
• RNA Polymerase Inhibitors
• Combination Antiviral Therapies
• Reverse Transcriptase Inhibitors

By Indication

• HIV/AIDS
• Hepatitis
• Influenza
• Herpes Simplex Virus (HSV)
• Human Papillomavirus (HPV)
• Others

By Drug Type

• Small Molecule Antivirals
• Biologics Antivirals
• RNA-based Therapies.

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Antiviral Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/antiviral-drug-market